Global clinical development has never been more complex. Sponsors are managing multi-country protocols, tightening regulatory timelines, and dealing with fragmented vendor networks, all amid growing pressure to deliver submission-ready data faster and at lower cost.

The global Contract Research Organization (CRO) services market is projected to reach USD 125.95 billion by 2030, with a growing CAGR of 8.3%, reflecting the heavy reliance of pharmaceutical and biopharmaceutical sponsors on external partners to execute clinical programs. 

Yet growth in outsourcing does not automatically translate to fewer execution problems. The challenges that delay Phase II and Phase III trials, from patient recruitment failures to multi-country regulatory bottlenecks, remain persistent and expensive. Understanding where these failure points occur and how capable CROs are structured to solve them is what separates successful program delivery from costly mid-trial course corrections.

This blog covers the most consequential challenges in global clinical development today and explains how experienced CROs address them across every stage of the trial lifecycle.

Why Global Clinical Trials Are Getting Harder to Execute?

Before examining individual challenges, it is worth understanding why the environment itself has become more difficult.

Clinical trial protocols have grown significantly more complex over the past decade. More endpoints, tighter eligibility criteria, larger site networks, and multi-jurisdictional regulatory requirements have all increased the operational burden on sponsors and their CRO partners.

Today’s clinical trials collect approximately three times as much data as they did 10 years ago, and it comes from a growing number of sources, making it no longer feasible to manually collect, monitor, clean, and analyze millions of data points from a single trial.

At the same time, emerging biopharma companies (EBPs), primarily pre-commercial organizations, lack the in-house infrastructure to manage multi-country operations independently. This creates a direct dependency on CRO partners who can provide the operational, regulatory, and scientific depth required.

Challenge 1: Patient Recruitment and Enrollment Failures

Patient recruitment is the most documented and costly failure point in global clinical development.

Globally, 55% of clinical trials have been terminated due to low recruitment, with an average enrollment success rate of just 40% for Phase III and Phase IV trials. These figures represent more than schedule delays. They represent failed programs, wasted capital, and delayed patient access to therapies.

The root causes include:

• Protocols with overly restrictive eligibility criteria.
• Limited awareness of the patient pool at investigative sites.
• Inadequate site selection based on poor feasibility data.
• Over-reliance on single-country recruitment strategies.
• Insufficient investigator engagement and site support.

How CROs Address This

Experienced CROs approach recruitment as a prospective planning exercise rather than a reactive response to enrollment shortfalls.

Recruitment Challenge	CRO Solution
Poor site selection	Risk-based feasibility assessment before site activation.
Enrollment shortfalls	Pre-built backup sites and secondary recruitment channels.
Diverse patient populations	Multi-country site networks with local investigator relationships.
Retention failures	Patient support programs (PSPs) and decentralized visit options.
Delayed ethics approvals	In-country regulatory experience and pre-submission site engagement.

Site feasibility, investigator networks, and alternative enrollment pathways must be built into the protocol design phase, not added after recruitment stalls.

For sponsors managing Phase II and Phase III programs across multiple geographies, DRK Research offers a structured site feasibility and patient recruitment framework backed by on-ground investigator networks and risk-based project planning, designed to reduce enrollment delays before they affect the overall study timeline.

Challenge 2: Multi-Country Regulatory Complexity

Running a Phase III trial across 10 or more countries means navigating 10 or more regulatory environments simultaneously. Ethics committee timelines, drug import licensing, National Competent Authority (NCA) submissions, and country-specific informed consent requirements all vary considerably.

A single delayed country approval can compress the entire enrollment window, trigger protocol amendments, and add months to the study timeline.

Key regulatory pressure points in global trials include:

• Variable ethics committee review timelines across jurisdictions.
• Drug import license requirements and Investigational Medicinal Product (IMP) customs clearance.
• Differing informed consent and data protection requirements.
• Inconsistent interpretation of the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines at the country level.
• Post-ICH E6(R3) adoption gaps across regulatory authorities.

The International Council for Harmonisation (ICH) officially adopted E6(R3) in early 2025, replacing the previous prescriptive approach with a more principle-based framework that emphasizes quality by design (QbD), risk-proportionate management, and evidence-based decision-making throughout the clinical trial lifecycle.

How CROs Address This

CROs with multi-jurisdiction regulatory experience build country-specific submission strategies from day one of study design. This includes:

• Pre-assessed ethics timelines and authority approval histories by country.
• Regulatory submission tracking across concurrent countries.
• IMP import and customs coordination aligned with study start-up milestones.
• Trial Master File (TMF) setup compliant with EMA, FDA, and local authority expectations.
• ICH-GCP E6(R3) aligned quality management systems.

Regulatory delays are rarely unpredictable when an experienced CRO has operated in those specific geographies before.

Challenge 3: Monitoring Gaps and Protocol Deviation Risk

Clinical monitoring is the operational mechanism that maintains data integrity, site compliance, and patient safety across the trial. When monitoring is inadequate, deviations accumulate, the database lock is delayed, and the Clinical Study Report (CSR) is at risk of regulatory acceptance.

The challenge is that traditional on-site monitoring is resource-intensive, expensive, and logistically difficult to scale across multi-country trials. Many sponsors have attempted to reduce costs by cutting monitoring frequency, which introduces greater risk exposure rather than reducing it.

Protocol deviations are particularly damaging in late-phase programs because they affect the scientific credibility of the data submitted to the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

How CROs Address This

Modern CROs apply hybrid monitoring models that combine:

• On-site monitoring: Direct investigator oversight, source data verification, and site relationship management.
• Centralized monitoring: Remote data review using electronic data capture (EDC) systems, risk-based triggers, and signal detection algorithms.
• Risk-Based Monitoring (RBM): Dynamic monitoring allocation based on site risk scores, protocol complexity, and real-time data quality indicators.

This approach does not reduce oversight. It reallocates monitoring effort toward where risk is highest, enabling earlier detection of protocol deviations, faster query resolution, and a tighter path to database lock.

eClinical platforms, including electronic data capture (EDC), Clinical Trial Management Systems (CTMS), Interactive Response Technologies (IRT), and eConsent, provide the infrastructure that makes centralized monitoring operationally viable.

Challenge 4: Serious Adverse Event Reporting and Pharmacovigilance Compliance

Serious Adverse Event (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting failures are among the most consequential risks in clinical trial execution. Regulatory authorities expect strict timelines, documented follow-up, and complete signal characterization. Incomplete or delayed safety reporting directly jeopardizes the outcomes of regulatory submissions.

In multi-country trials, pharmacovigilance (PV) complexity increases significantly because reporting timelines, local health authority notification requirements, and expedited reporting obligations vary by jurisdiction.

Common failure modes include:

• SAE documentation gaps at the site level.
• Delayed escalation from clinical monitors to the safety team.
• Inconsistent signal assessment across countries.
• Poor integration between the clinical and safety databases.
• Incomplete investigator notifications within regulatory timeframes.

How CROs Address This

Full-service CROs integrate pharmacovigilance operations directly into clinical trial management rather than treating it as a separate function. This means:

• Real-time capture of adverse events (AEs) within the EDC system.
• Medical monitor review of safety signals throughout the study.
• Submission-ready safety narratives and expedited reporting to health authorities.
• End-to-end PV documentation aligned with EMA and FDA expectations.
• Biostatistics integration for safety data analysis ahead of CSR preparation.

The goal is an unbroken chain from site-level event detection to regulatory submission, with no documentation gaps.

Challenge 5: Fragmented Vendor Management

A significant operational risk in global clinical development is vendor fragmentation. Sponsors who manage separate contracts with laboratories, couriers, CROs, Site Management Organizations (SMOs), technology vendors, and medical writing teams face coordination overhead, communication delays, and accountability gaps that compound over the course of a multi-year program.

Each handoff between vendors is a potential failure point. Delayed lab results, unclear IMP accountability, misaligned monitoring timelines, and inconsistent data formats are all downstream consequences of fragmented vendor ecosystems.

How CROs Address This

The move toward full-service CRO partnerships reflects sponsors’ need for a single point of accountability across the trial lifecycle. Under this model, the CRO assumes coordination responsibility for:

Function	CRO-Managed Scope
Laboratory coordination	Central lab selection, sample logistics, and results integration.
IMP accountability	Drug import, storage, reconciliation, and destruction.
Technology vendors	EDC, CTMS, IRT, and eConsent platform management.
Medical writing	Protocol development, CSR preparation, and regulatory documentation.
SMO coordination	Site activation, investigator training, and performance oversight.

This consolidation reduces sponsor oversight burden, shortens communication chains, and improves timeline predictability across the study.

Challenge 6: Decentralized and Hybrid Trial Execution

Decentralized Clinical Trials (DCTs) have moved from pilot-stage experiments to a recognized operational model. They offer clear advantages in patient access, retention, and enrollment efficiency. However, they also introduce new complexity in data governance, remote monitoring compliance, and regulatory alignment.

Hybrid trials, which combine traditional on-site activities with remote and virtual components, require CROs to manage a wider set of operational variables simultaneously.

Key DCT execution challenges include:

• Integration of a telemedicine platform with existing clinical data systems.
• Remote patient visit documentation aligned with ICH-GCP E6(R3).
• Home nursing coordination and remote investigational product delivery.
• Data security and patient privacy across decentralized touchpoints.
• Regulatory acceptability of remotely collected source data.

How CROs Address This

CROs with established DCT capabilities build decentralized components into the protocol from the design phase. This includes remote patient engagement infrastructure, oversight of digital monitoring, and telemedicine frameworks that meet current FDA and EMA guidance on decentralized elements in clinical trials.

Integrated DCT delivery reduces patient dropout, expands the eligible participant pool, and supports faster enrollment without compromising data integrity or regulatory acceptability.

How the Right CRO Partner Changes Clinical Trial Outcomes?

The individual challenges covered above rarely occur in isolation. Recruitment delays compress regulatory timelines. Monitoring gaps lead to data quality issues that delay the database lock. Fragmented vendor management amplifies both.

When these problems stack, they do not just add cost. They put the entire program at risk.

CROs that operate under risk-based, resilience-first project management frameworks pre-build contingency pathways into study design. This includes:

• Alternative site lists are activated before primary enrollment stalls
• Backup IMP import routes planned ahead of study start-up
• Secondary patient recruitment channels pre-identified during feasibility
• Country-specific regulatory timelines are built into the master project plan

This is not reactive problem-solving. It is a proactive trial architecture.

DRK Research applies this model across Phase II and Phase III programs, managing feasibility through study start-up (SSU), recruitment, monitoring, safety reporting, and Clinical Study Report (CSR) preparation under a single operational framework. Their hybrid monitoring infrastructure, AI-assisted oversight dashboards, and integrated pharmacovigilance model are designed to reduce protocol deviations and enable faster, cleaner database lock for complex, multi-country studies.

For pharmaceutical and biopharmaceutical sponsors evaluating CRO partners, the core question is not simply whether a CRO can run a trial. It is whether they have the systems, geography, and regulatory depth to protect the program when execution pressure builds.

Conclusion

Global clinical development challenges are predictable. What varies is how well-prepared a sponsor and their CRO partner are to manage them before they become program-level risks.

Patient recruitment failures, regulatory delays, monitoring gaps, and vendor fragmentation do not emerge without warning. They emerge when feasibility planning is shallow, oversight is reactive, and operational accountability is split across too many parties.

The CRO model works when it is built around full lifecycle ownership, risk-based execution, and regulatory alignment from day one. Sponsors who evaluate partners on those criteria, rather than cost alone, consistently see better data quality, tighter timelines, and stronger submission outcomes.

Partner selection is a clinical decision. Treat it accordingly.